Stakeholders say EMA's proposed PV fees are too high

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.668, 2012-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Stakeholders say EMA's proposed pharmacovigilance fees are too high

By  

Reactions Weekly, Vol. 1, Iss. 1431, 2012-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA

By Karalis Vangelis   Symillides Mira   Macheras Panos  

Pharmaceutical Research, Vol. 29, Iss. 4, 2012-04 ,pp. : 1066-1077

Springer Publishing Company

Access to resources Recommend Favorite

US President Obama's proposed 2011 budget includes generic drug user fees

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 596, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

LH in the follicular phase: neither too high nor too low

By Balasch Juan   Fábregues Francisco  

Reproductive BioMedicine Online, Vol. 12, Iss. 4, 2006-04 ,pp. : 406-415

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Recommended lepirudin dose for HIT is too high

By  

Inpharma, Vol. 1, Iss. 1557, 2006-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite